M
Mercè Brunet
Researcher at University of Barcelona
Publications - 103
Citations - 4090
Mercè Brunet is an academic researcher from University of Barcelona. The author has contributed to research in topics: Transplantation & Tacrolimus. The author has an hindex of 30, co-authored 98 publications receiving 3369 citations. Previous affiliations of Mercè Brunet include Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
Maria Varela,Maria Isabel Real,Marta Burrel,Alejandro Forner,Margarita Sala,Mercè Brunet,Carmen Ayuso,Lluis Castells,Xavier Montaña,Josep M. Llovet,Jordi Bruix +10 more
TL;DR: Chemoembolization using DEBs is an effective procedure with a favorable pharmacokinetic profile and after a median follow-up of 27.6 months, 1- and 2-year survival is 92.5% and 88.9%, respectively.
Journal ArticleDOI
Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
Pierre Wallemacq,Victor W. Armstrong,Mercè Brunet,Vincent Haufroid,David W. Holt,Atholl Johnston,Dirk Kuypers,Yannick Le Meur,Pierre Marquet,Michael Oellerich,Eric Thervet,Burkhand Toenshoff,Nas Undre,Lutz T. Weber,Ian S. Westley,Michel Mourad +15 more
TL;DR: The importance of obtaining multicenter prospective trials to assess the efficacy of alternative strategies to TAC trough concentrations is emphasized, and single time points, limited sampling strategies, and area under concentration-time curve have all been considered to determine the most appropriate sampling procedure that correlates with efficacy.
Journal ArticleDOI
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy : Second Consensus Report
Mercè Brunet,Teun van Gelder,Anders Åsberg,Vincent Haufroid,Vincent Haufroid,Dennis A. Hesselink,Loralie J. Langman,Florian Lemaitre,Pierre Marquet,Christoph Seger,Maria Shipkova,Alexander A. Vinks,Alexander A. Vinks,Pierre Wallemacq,Eberhard Wieland,Jean-Baptiste Woillard,Markus J. Barten,Klemens Budde,Helena Colom,Maja Theresa Dieterlen,Laure Elens,Kamisha L. Johnson-Davis,Paweł K. Kunicki,Iain MacPhee,Satohiro Masuda,Binu S. Mathew,Olga Millán,Tomoyuki Mizuno,Tomoyuki Mizuno,Dirk Jan A.R. Moes,Caroline Monchaud,Ofelia Noceti,Tomasz Pawinski,Nicolas Picard,Ron H.N. van Schaik,Claudia Sommerer,Nils Tore Vethe,Brenda C. M. de Winter,Uwe Christians,Stein Bergan +39 more
TL;DR: It is concluded that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade, and the Expert Committee concludes that Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacolimus therapy and to improve long-term outcomes for treated patients.
Journal ArticleDOI
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
Susan E. Tett,Franck Saint-Marcoux,Franck Saint-Marcoux,Christine E. Staatz,Mercè Brunet,Alexander A. Vinks,Masatomo Miura,Pierre Marquet,Pierre Marquet,Dirk Kuypers,Teun van Gelder,Dario Cattaneo +11 more
TL;DR: MPA exposure should be measured and doses should be adjusted accordingly to achieve optimal clinical outcomes and limited sampling strategies to estimate MPA exposure from EC-MPS have not yet been well developed and fully evaluated, nor have accurate Bayesian estimators been reported.
Journal ArticleDOI
Therapeutic Drug Monitoring of Everolimus: A Consensus Report
Maria Shipkova,Dennis A. Hesselink,David W. Holt,Eliane M. Billaud,Teun van Gelder,Paweł K. Kunicki,Mercè Brunet,Klemens Budde,Markus J. Barten,Paolo De Simone,Eberhard Wieland,Olga López,Satohiro Masuda,Christoph Seger,Nicolas Picard,Michael Oellerich,Loralie J. Langman,Pierre Wallemacq,Raymond G. Morris,Carol Thompson,P. Marquet +20 more
TL;DR: EVR trough concentrations (C0) demonstrate a good relationship with overall exposure, providing a simple and reliable index for TDM, and a fully validated liquid chromatography tandem mass spectrometry assay is the preferred method for determination of EVR C0.